Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2021

Enhanced androgen signalling inhibition should be the treatment of choice for treatment of mCSPC rather than docetaxel

Polling 2 (led by chair)

Date

20 Sep 2021

Session

Enhanced androgen signalling inhibition should be the treatment of choice for treatment of mCSPC rather than docetaxel

Presenters

Eleni Efstathiou

Authors

E. Efstathiou

Author affiliations

  • Gu Medical Oncology, The M.D. Anderson Cancer Center, 77030 - Houston/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

Introduction by the chair

Presenter: Eleni Efstathiou

Session: Enhanced androgen signalling inhibition should be the treatment of choice for treatment of mCSPC rather than docetaxel

Resources:

Slides

Webcast

Yes

Presenter: Karim Fizazi

Session: Enhanced androgen signalling inhibition should be the treatment of choice for treatment of mCSPC rather than docetaxel

Resources:

Slides

Webcast

No

Presenter: Ronald De Wit

Session: Enhanced androgen signalling inhibition should be the treatment of choice for treatment of mCSPC rather than docetaxel

Resources:

Slides

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.